Numerous studies have analyzed the expression and prognostic importance of various proteins in acute myelogenous leukemia (AML). We sought to determine whether the sample source and methodology used to measure protein expression affect the results obtained. To determine the importance of sample source, we used Western blotting to compare the expression of eight proteins and phosphoproteins in the leukemia blast-enriched fraction of 118 blood-and 108 marrow-derived samples, including 37 paired samples. To determine the importance of methodology, the expression of five proteins was measured in 20 paired samples by Western blotting, laser scanning cytometry (LSC), and flow cytometry. The mean expression and range of expression in blood-and marrow-derived samples were statistically identical for all eight proteins. Expression measurements for the 37 paired blood and marrow samples also had very high statistical correlation. The LSC and flow cytometry data had the highest concordance when compared using Kolmogorov-Smirnoff D-stats (range of R values, 0.8-1.0). High concordance was also observed between the LSC and flow cytometry results when the percentage of cells positive for expression was dichotomized into positive or negative expression. However, there was less correlation between LSC and flow cytometry when the actual percentages of positive cells were compared. The majority of discordant situations involved samples that were positive by flow cytometry but negative by LSC. The correlation between Western blotting signal intensity and the percentage of expression-positive cells measured by LSC or flow cytometry varied by protein but was limited when there was little heterogeneity in expression by either method. In conclusion, provided that leukemia blast-enriched fractions were analyzed, the blood-and marrow-derived samples had identical protein expression. There was good concordance of results between flow cytometry and LSC, which share similar technology, but more limited correlation between these methods and Western blotting.
Introduction
The analysis of protein expression and functional status is an integral part of many studies investigating leukemogenesis or leukemia cell function. This has been facilitated by the easy access to leukemic blasts from blood or bone marrow. However, it is unclear whether the expression or functional status of a given protein differs between bone marrow-and peripheral blood-derived leukemic blasts. This confounds the comparison of results from studies using blasts of different origins. Interpretation of results is also confounded by the variety of methodologies that are used to assess protein expression, including Western blotting, 1 flow cytometry analysis, 2 and laser scanning cytometry (LSC). 3, 4 A review of the literature did not yield any published reports comparing protein expression levels between blood-and marrow-derived leukemic samples. A few published manuscripts have compared protein expression measured by different methodologies, with two reporting excellent correlation 5, 6 and one reporting limited correlation. 7 However, none have systematically compared the importance of sample source or assay method to the measurement of specific protein expression in acute myelogenous leukemia (AML). The goal of the present study was to provide such a comparison.
As part of an ongoing research project, we have been prospectively collecting blood and marrow specimens, sometimes simultaneously, from newly diagnosed AML patients. We analyzed the expression and functional status (phosphorylation) of proteins in these samples by Western blotting, flow cytometry, and LSC to determine whether measurements of these characteristics differ between blood-and marrow-derived blasts and between assay methodologies.
Materials and methods

Study group
Peripheral blood or leukopheresis specimens (n ¼ 118) and bone marrow specimens (n ¼ 108) were collected during routine diagnostic assessments of newly diagnosed AML patients evaluated at The University of Texas MD Anderson Cancer Center between 1 September 1999, and 1 January 2004. Simultaneous blood and marrow specimens were available from 37 of these patients. Samples were acquired in accordance with regulations and protocols sanctioned by the institution's investigational review board. Written informed consent was obtained from all patients.
Sample processing
Samples were placed on ice immediately after collection and were processed within 2 h of collection. Mononuclear cells were isolated by fractionation with Ficoll-Hypaque (Pharmacia, Piscataway, NJ, USA). The mean and median percentages of leukemic blasts before Ficoll separation were 60.9 and 64%, respectively, in bone marrow-derived specimens and 46.1 and 47.5%, respectively, in peripheral blood-derived specimens. Samples calculated to have more than 5% lymphocytes after Ficoll separation, based on the pre-Ficoll differential, were further purified by CD3/CD19 separation using magnetic antibody-conjugated sorting (Miltenyi Biotec, Auburn, CA, USA) to yield leukemia blast-enriched cell fractions. The cells were used to make whole-cell lysates for Western blotting, cryopreserved, or used fresh for flow cytometry and LSC analysis.
Western blotting
Lysates from 4.5 Â 10 5. cells were subjected to Western blotting using the Criterion system (Bio-Rad, Hercules, CA, USA). Bone marrow-and peripheral blood-derived samples were loaded on the same blot along with an aliquot from a bulk preparation of control cell lines (K562 and Jurkat) and molecular weight markers. Triplicate membranes were created for each sample. The first blot was probed with a monoclonal antibody against phosphorylated ERK2 (pERK2; 1 : 1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA), stripped, and reprobed with an antibody against total AKT (1 : 1000; Cell Signaling Technologies, Beverly, MA, USA). The second blot was probed with an antibody against phosphorylated AKT (pAKT; 1 : 1000; Cell Signaling Technologies), stripped, and reprobed with a monoclonal antibody against total ERK2 (1 : 1000; Santa Cruz Biotechnology) and an antibody against BCL2 (1 : 2000; Dako, Carpinteria, CA, USA). The third blot was probed with antibodies against PKC-a (1 : 500; Santa Cruz Biotechnologies) and Bax (1 : 1000; Cell Signaling Technologies), stripped, and reprobed with an antiactin antibody (1 : 2000; Sigma-Aldrich, St Louis, MO, USA). After incubation with the primary antibodies, each membrane was subjected to three 15-min washes in phosphate-buffered saline with Tween-20 (PBS-T) at room temperature. The membranes were then exposed to sheep anti-mouse immunoglobulin G (IgG) conjugated to horseradish peroxidase (Amersham Life Science, Arlington Heights, IL, USA) at a 1:2000 dilution in PBS-T for 0.5 h and then subjected to another three 15-min washes in PBS-T at room temperature. The membranes were exposed to SuperSignal West Dura extendedduration substrate (Pierce Biotechnology, Rockville, IL, USA) for 5 min, in accordance with the manufacturer's recommendations, and then directly imaged and quantitated in a ChemiImager 4400 low-light imaging system (Alpha Innotech, San Leandro, CA, USA). The results were normalized against either the expression of the same protein in a standardized protein preparation from an AML cell line (K562 or Jurkat) or against the expression of actin in the same patient's sample. Analysis of the prognostic importance of the expression of these proteins is outside the scope of this report.
LSC
Cells from fresh blood and bone marrow samples were resuspended in PBS at approximately 4 Â 10 5 cells/ml, attached electrostatically to poly-lysine-coated slides (Shandon, Pittsburgh, PA, USA), and fixed with 1% paraformaldehyde at pH 7.4 for 15 min at 41C. After being washed twice with PBS, cells were permeabilized with 0.1% Triton X-100 and treated with a blocking solution containing 5% goat serum and 0.1% Tween-20 in PBS. Some samples were subsequently incubated with fluorescein isothiocyanate (FITC)-conjugated antibodies to human BCL2 (1 : 5; DAKO) or pERK (1 : 5; Biosource International, Camarillo, CA, USA) for 30 min at room temperature. Other samples were incubated with FITC-conjugated antibodies against PKC-a or ERK2 (1 : 50; Santa Cruz Biotechnology) or Bax (1 : 100; Coulter-Immunotech, Miami, FL, USA) for 2 h at room temperature. The cells were then washed and incubated with a FITC-conjugated secondary antibody at room temperature for 30 min. Isotype immunoglobulin binding was performed as a control. After additional washing, cells were counterstained with 200 mg/ml RNase and 10 mg/ml 7-aminoactinomycin D (Molecular Probes, Eugene, OR, USA) for 30 min and mounted with mounting medium for fluorescence measurement (Vector Laboratories, Burlingame, CA, USA).
LSC analysis was performed using a CompuCyte (Cambridge, MA, USA) laser scanning cytometer with analysis by WinCyte 3.1 PC-based software in the MD Anderson Cell and Tissue Analysis Core Facility. The slides were scanned using a Â 20 objective and an argon laser. The cells were identified and selected by contouring on the basis of 7-aminoactinomycin D fluorescence and minimum cell size. Antigen immunofluorescence and DNA-associated 7-aminoactinomycin D fluorescence emissions were excited at 488 nm and measured using standard 530-nm band-pass and 650-nm long-pass filters, respectively. All experiments described contained a maximum of 2000 scanned events.
Flow cytometry
Flow cytometry was performed using specimens cryopreserved in medium containing 10% dimethylsulfoxide and 20% fetal bovine serum. Specimens were thawed to room temperature and washed twice in PBS. Approximately 2.5 Â 10 6 cells were stained with each antibody. Cells were fixed in 1 ml of 2% icecold paraformaldehyde in PBS on ice for 1 h and then washed twice with PBS. The pellet was resuspended in 1.9 ml of PBS with 100 ml of 10% Tween-20 in normal saline, gently vortexed, incubated on ice for 15 min, washed twice with PBS, and incubated in PBS with the following primary antibodies: FITCconjugated anti-BCL2 monoclonal antibody (1 : 5; DAKO), FITC-conjugated anti-pERK monoclonal antibody (1 : 5; Biosource International), anti-PKC-a and anti-pERK monoclonal antibodies (1 : 50; Santa Cruz Biotechnology), and FITC-conjugated anti-Bax monoclonal antibody (1 : 100; Coulter-Immunotech). After incubation with antibodies on ice for 15 min, the cells were washed and incubated with a FITC-conjugated secondary antibody on ice for a further 15 min. The cells were then washed twice with PBS, resuspended in 1.9 ml of PBS, and allowed to incubate for 30 min on ice. After this incubation, 100 ml of 10% Tween-20 in PBS was added while the cells were gently vortexed. The cells were kept in this solution overnight at 41C. The next day, the 10% Tween-20/PBS solution was washed out and 500 ml of PBS was added. The cells were analyzed by flow cytometry using an LSR bench top flow cytometer (BD Biosciences, San Jose, CA, USA), with data analysis by BD CellQuest Pro software. Isotype immunoglobulin binding was performed as a control. Samples were considered to have positive expression if the signal intensity of 20% or more of the sample cells was greater than the signal intensity of 98% of the isotype control cells. All experiments described contained a maximum of 10 000 events.
Statistical analysis
The mean and normality of the variance of protein expression in blood-derived and marrow-derived samples, as measured by Western blotting, were compared using the t-test and F-test, respectively. The Pearson correlation between the expression levels in matched bone marrow-and peripheral blood-derived samples was estimated using the least-squares method. The percentage of positivity and the Kolmogorov-Smirnov D-stat results obtained by LSC were compared with those obtained by flow cytometry using the Pearson correlation. All tests were performed using Statistica version 6.0 software (StatSoft, Tulsa, OK, USA). For all tests P-values p0.05 were considered significant
Results
Comparison of protein expression in bloodand marrow-derived samples
We used Western blotting to analyze the expression of Bax, BCL2, PKC-a, ERK, AKT, and actin. We also assessed the phosphorylation status of ERK and AKT. We analyzed a total of 118 blood-derived samples and 108 marrow-derived samples, including matched samples from 37 patients. A composite blot showing the expression of each of the eight proteins measured in eight patients is shown in Figure 1 . The mean and variance of expression levels for each of the proteins were statistically indistinguishable in the blood-and marrow-derived samples ( Figure 2 and Table 1 ). For the matched samples, the correlation coefficients for specific protein expression levels in blood and marrow were high, and the correlations were highly statistically significant ( Figure 3 and Table 1 ).
Comparison of protein expression measurements by different methodologies
We first assessed protein expression measurements by flow cytometry and LSC using 20 cryopreserved samples for which Western blotting data had already been obtained. Comparisons of LSC and flow cytometry data using Kolmogorov-Smirnoff D-stats demonstrated the highest concordance (Table 2) . High concordance between the LSC and flow cytometry results was also observed when the protein expression was compared in terms of positivity or negativity ( Table 3 ). The majority of discordant situations involved samples that were positive by flow cytometry but negative by LSC. In contrast, there was only modest correlation between methods when the actual percentages of expression-positive cells were compared (data not shown).
Western blotting measures signal strength by integrating the protein expression for an entire population of cells, whereas flow cytometry and LSC measure signal intensity within single cells and develop population histograms representing either the percentage of cells expressing a protein or the mean channel fluorescence of a population of cells. Thus, the lack of correlation found between measurements taken by Western blotting and flow cytometry or LSC was expected, since they do not measure the same endpoint (Table 4) .
Discussion
We have analyzed in primary AML samples, the relative expression of six proteins and the phosphorylation status of two of those proteins, all of which have established importance in the regulation of proliferation and survival. 1, [8] [9] [10] We found that the source of the AML samples does not appear to be important as long as effectively leukemia blast-enriched fractions are used. In contrast, the method used for analysis can give different results for some proteins.
We found that the expression of each of these proteins was similar in Western blot assays regardless of whether the leukemia cells were derived from blood or bone marrow. This was true for both the mean expression and the overall variance in the range of expression. Protein expression levels were also significantly correlated in matched blood and marrow samples. The presence of pERK and pAKT was also highly correlated in assays of blood and marrow samples, both in terms of mean and variance of expression, and data from matched samples were highly correlated. This is important because the functional, or phosphorylation, status of proteins may be more important prognostically than the absolute expression levels. Thus, our data imply that the source of AML samples does not affect the analysis of protein expression, provided that leukemia blastenriched samples are used. Regression plots comparing data from matched blood and marrow specimens for seven different proteins and phosphoproteins. Data shown as P ¼ 0.0000 had P-values o0.0001.
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We believe that it is important to generate leukemia blastenriched fractions by Ficoll separation to remove granulocytes and red blood cells and by magnetic antibody-conjugated sorting to remove contaminating CD3/CD19-positive lymphocytes. This is presumably most important in blood samples, which typically contain a lower percentage of leukemic blasts than do marrow samples. Although we did not compare protein expression in blood samples that were not depleted of CD3/CD19 cells, we observed high BCL2 expression in the CD3/CD19-positive fraction in a small number of analyzed samples (data not shown), consistent with published data in lymphoid cells. 11 This suggests that contaminating lymphoid cells could markedly affect the measured expression of many proteins if those cells are not removed. Consequently, our results cannot be generalized to comparisons of unenriched leukemic samples from blood and marrow, and we do not know whether our conclusions can be generalized to all proteins that might be present in blood and marrow samples. Proteins whose expression varies by cell-cycle stage and cell proliferation rate might show greater differences between blood and marrow samples. However, the lack of statistical differences in any of the eight proteins that we analyzed suggests that our conclusion may apply to the analysis of many proteins and that blood and marrow samples can be used interchangeably, provided that contaminating lymphocytes are removed.
LSC and flow cytometry are similar, sensitive methods of quantifying, the amounts of protein per cell. The rate of scanning and data acquisition is considerably slower in LSC than in flow cytometry, but LSC can measure protein levels with much smaller numbers of cells than are required for flow cytometry. 2, 4, [12] [13] [14] In this study, there was good concordance between LSC and flow cytometry with respect to determining whether expression was present or absent, when either the D-stat or the percentage of cells that were positive was compared. However the methods demonstrated only modest correlation between the percentage of expression-positive cells (using a cutoff of 20% with expression 4isotype control). The majority of discordant situations involved samples that were considered positive by flow cytometry but negative by LSC. Since the level of expression detected by LSC was usually lower than that detected by flow cytometry, our findings suggest that LSC is less sensitive than flow cytometry. The correlation between proteins levels measured by Western blotting and either the percentage of positive cells or the mean channel fluorescence measured by LSC or flow cytometry varied by protein but was generally not statistically significant. In the case of PKC-a, the absence of a correlation was due to a lack of heterogeneity in the flow cytometry and LSC measurements compared to the broad heterogeneity seen with Western blotting. This result was expected since Western blotting is based on population averages, in contrast to the single-cell measurements obtained by flow cytometry or LSC. Our results are dissimilar to those of Nuessler et al, 5 who observed no difference between BCL2, Bax, or BCL-XL expression as measured by flow cytometry and Western blotting in leukemia cell lines. However, cultured cells are much more homogeneous than cells in patient-derived samples with respect to proliferation rate, size, and protein content. Thus, it is not surprising that a correlation between methods was observed with cell lines but not with patient samples.
To our knowledge, this is the first time that protein expression in patient-derived AML material has been compared between blood and marrow sources and between different methods. These findings may also have relevance to other diseases where malignant cells can be collected from blood or bone marrow including; acute and chronic lymphocytic leukemia, myelodysplasia, chronic myelogenous leukemia, myeloma, and lymphoma. Flow cytometry and LSC showed relatively homogeneous expression of PKC-a and Bax, whereas Western blotting showed more heterogeneous expression among the population of patients studied. Such discordance between techniques may account for the different observations regarding the prognostic importance of these proteins in AML. 9, [15] [16] [17] [18] [19] [20] Our findings stress the importance of considering the strengths and weaknesses of each method when analyzing the prognostic or functional importance of a particular protein. Effect of sample source on protein expression in AML SM Kornblau et al
